Preprint
via Europe PMC
A mesoporous oxygen-vacancy-rich ZnO nanoplatform as a catalytic therapeutic hub for osteoarthritis therapy by TRIM15-targeted stem cell rejuvenation
Liu B, Zhang Z, Zhang C, Liu P, Xiong Z, Li Y, Zhang Q, Chen H, Zhang H, Huang C.
· 2026
Mitochondrial dysfunction
Cellular senescence
Stem-cell exhaustion
Chronic inflammation
Disabled macroautophagy
Mouse
Abstract
<title>Abstract</title> <p> Osteoarthritis (OA) lacks disease-modifying treatments, partly because aging creates an oxidative-senescent joint niche that accelerates cartilage degeneration and weakens endogenous MSC-mediated repair. We found that aged OA cartilage harboured TRIM15-high MSC-like cells, whereas aged joint-derived MSCs exhibited zinc depletion, defective mitophagy and impaired chondrogenesis. To address these abnormalities, we developed oxygen-vacancy-rich mesoporous ZnO (meso-ZnO <sub>v</sub> ) as an active therapeutic material capable of scavenging reactive oxygen species and restoring zinc homeostasis through Zn <sup>2+</sup> release. Here, we incorporated a Zn <sup>2+</sup> -dependent TRIM15-targeting DNAzyme into meso-ZnO <sub>v</sub> and coated this active core with an ITGA2-enriched hybrid membrane to generate ZDM. ZDM preferentially accumulated in damaged cartilage and enhanced tissue penetration. It alleviated oxidative stress and senescence(definition) and restored cartilage matrix homeostasis, while re-establishing zinc homeostasis and rejuvenating aged MSCs. Mechanistically, ZDM reduced TRIM15 abundance and YAP nuclear localisation and restored SOX9 expression and PINK1-dependent mitophagy, thereby reversing MSC senescence and promoting chondrogenesis. In aged mouse and beagle OA models, ZDM improved joint function, preserved cartilage and subchondral bone, and reduced synovial inflammation. These findings establish a meso-ZnO <sub>v</sub> -based nanotherapeutic strategy that couples microenvironmental restoration with stem-cell rejuvenation, offering a promising disease-modifying approach for age-associated OA. </p>
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.21203/rs.3.rs-10146539/v1
- Canonical
- link ↗
- Fetched
- 2026-10-11 MST
Cite this
APA
B, L., Z, Z., C, Z., P, L., Z, X., Y, L., Q, Z., H, C., H, Z., & C., H. (2026). A mesoporous oxygen-vacancy-rich ZnO nanoplatform as a catalytic therapeutic hub for osteoarthritis therapy by TRIM15-targeted stem cell rejuvenation. https://doi.org/10.21203/rs.3.rs-10146539/v1
Vancouver
B L, Z Z, C Z, P L, Z X, Y L, et al. A mesoporous oxygen-vacancy-rich ZnO nanoplatform as a catalytic therapeutic hub for osteoarthritis therapy by TRIM15-targeted stem cell rejuvenation. 2026. doi:10.21203/rs.3.rs-10146539/v1.
BibTeX
@unpublished{liu2026Amesop,
title = {A mesoporous oxygen-vacancy-rich ZnO nanoplatform as a catalytic therapeutic hub for osteoarthritis therapy by TRIM15-targeted stem cell rejuvenation},
author = {Liu B and Zhang Z and Zhang C and Liu P and Xiong Z and Li Y and Zhang Q and Chen H and Zhang H and Huang C.},
year = {2026},
doi = {10.21203/rs.3.rs-10146539/v1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Research Square 2026
Preprint · CC-BY
A mesoporous oxygen-vacancy-rich ZnO nanoplatform as a catalytic therapeutic hub for osteoarthritis therapy by TRIM15-targeted stem cell rejuvenation
Theranostics 2026
Open access · CC-BY
ARG2 drives osteoblast senescence by repressing mitophagy via the IκB–NF-κB–TXN2 signaling axis: implications for age-associated osteoporosis
bioRxiv (Cold Spring Harbor Laboratory) 2022
Preprint · CC-BY
Chemical reprogramming ameliorates cellular hallmarks of aging and extends lifespan
ACS applied materials & interfaces 2026
Citation only
ROS-Responsive H<sub>2</sub>S Release Attenuates Renal Aging by Preserving Mitochondrial Function and Mitigating Oxidative Stress.
BioEssays 2023
Open access · CC-BY
Epigenetic rejuvenation by partial reprogramming
EMBO molecular medicine 2025
Open access · OA